Gene · 53353
Papers2,235
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 2,235
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Integrating bulk and single-cell data to predict the prognosis and identify the immune landscape in HNSCC. | J Cell Mol Med | 2024 | 37882107 | PubTator, text mining | PubMed |
| The correlation between clinical outcomes and genomic analysis with high risk factors for the progression of osteosarcoma. | Mol Oncol | 2024 | 37727135 | PubTator, text mining | PubMed |
| Identification of TP53 mutation-associated prognostic genes and investigation of the immune cell infiltration in patients with hepatocellular carcinoma. | Genes Dis | 2024 | 37692491 | PubTator, text mining | PubMed |
| Distinct clinical profiles and mutation landscapes of gliomas originating from the neocortex, mesocortex, and cerebellum. | Genes Dis | 2024 | 37588233 | PubTator, text mining | PubMed |
| The Relationship Between Gene Mutations and the Clinicopathological Features and Prognosis of Gastric Cancer. | Int J Surg Pathol | 2024 | 37545327 | PubTator, text mining | PubMed |
| Characteristics and prognosis of EGFR mutations in small cell lung cancer patients in the NGS era. | Clin Transl Oncol | 2024 | 37436674 | PubTator, text mining | PubMed |
| Gene fusions during the early evolution of mesothelioma correlate with impaired DNA repair and Hippo pathways. | Genes Chromosomes Cancer | 2024 | 37421230 | PubTator, text mining | PubMed |
| Genomic landscape in Saudi patients with hepatocellular carcinoma using whole-genome sequencing: a pilot study. | Front Gastroenterol (Lausanne) | 2023 | 41821813 | PubTator, text mining | PubMed |
| Tislelizumab plus nimotuzumab is effective against recurrent or metastatic oral squamous cell carcinoma among patients with a performance status score ≥ 2: a retrospective study. | Front Oncol | 2023 | 38293699 | PubTator, text mining | PubMed |
| Dissecting the genetic variations associated with response to first-line chemotherapy in patients with small cell lung cancer: a retrospective cohort study. | J Thorac Dis | 2023 | 38249933 | PubTator, text mining | PubMed |
| DNA replication in early mammalian embryos is patterned, predisposing lamina-associated regions to fragility. | bioRxiv | 2023 | 38234839 | PubTator, text mining | PubMed |
| Mutational separation and clinical outcomes of TP53 and CDH1 in gastric cancer. | World J Gastrointest Surg | 2023 | 38222005 | PubTator, text mining | PubMed |
| Prognostic Significance of Tumor Mutation Burden among Patients with Non-small Cell Lung Cancer Who Received Platinum-based Adjuvant Chemotherapy: An Exploratory Study. | J Cancer Prev | 2023 | 38205359 | PubTator, text mining | PubMed |
| Molecular Profile of Intrahepatic Cholangiocarcinoma. | Int J Mol Sci | 2023 | 38203635 | PubTator, text mining | PubMed |
| A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy. | Int J Mol Sci | 2023 | 38203214 | PubTator, text mining | PubMed |
| Clinical Application of the Association between Genetic Alteration and Intraoperative Fluorescence Activity of 5-Aminolevulinic Acid during the Resection of Brain Metastasis of Lung Adenocarcinoma. | Cancers (Basel) | 2023 | 38201516 | PubTator, text mining | PubMed |
| Intragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4331 Solid Tumors. | Cancers (Basel) | 2023 | 38201434 | PubTator, text mining | PubMed |
| Predicting therapeutic responses in head and neck squamous cell carcinoma from TP53 mutation detected by cell-free DNA. | Transl Cancer Res | 2023 | 38197078 | PubTator, text mining | PubMed |
| Identification of cuproptosis and ferroptosis-related subgroups and development of a signature for predicting prognosis and tumor microenvironment landscape in hepatocellular carcinoma. | Transl Cancer Res | 2023 | 38192999 | PubTator, text mining | PubMed |
| Identification and validation of novel prognostic fatty acid metabolic gene signatures in colon adenocarcinoma through systematic approaches. | Oncol Res | 2023 | 38186579 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/53353/papers?page=10